July 13, 2015, Montréal, Canada – It is with pleasure to announce that Vantage BioTrials’ President, Vatché Bartekian, has been nominated by Ernst & Young for Entrepreneur of the Year 2015 in recognition of his vision, leadership and achievement in building a successful, growing and dynamic business.

“It is a great honor to be recognized by our peers, clients, colleagues and partners through this prestigious nomination.  Ernst & Young is a beacon of quality amongst the business management, accounting and finance industry, and similarly through the hard work of Vantage BioTrials’ employees we continue to establish ourselves as the go-to Canadian CRO for clinical trial management services.  This award is also shared by all of our employees who passionately perform their duties in order to protect the safety of the patients we care for in our clinical trials.  We pride ourselves each day for knowing that our work helps to bring to market safe and effective therapies for various conditions.” explains Vatché Bartekian.

About Vantage BioTrials Inc.

Vantage BioTrials Inc. is a leading Canadian Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to international biopharmaceutical, biotechnology, generic pharma and medical device companies within North America and Europe.

We are experts in implementing Risk-Based Management through the use of Quality by Design (QbD) methodologies, which helps accelerate the conduct of a study and reduces overall risk.  As a result this ensures that your trial is performed correctly, the first time!

For more information about Vantage BioTrials’ services and capabilities, please visit vantagebiotrials.com.

For more information

Vantage BioTrials, Inc.
Viken Bartekian
Co-Founder & Vice President of Business Development
[email protected]